, Singapore
257 views

SG acquires AstraZeneca's Evusheld

Evusheld is a long-acting antibody candidate for COVID-19 treatment.

The government of Singapore has signed a purchase agreement with AstraZeneca to deliver Evusheld, its long-acting antibody (LAAB) combination candidate, for the treatment of COVID-19.

The supply will arrive in Singapore by year-end.

"Evusheld provides healthcare professionals and patients in Singapore with a new option to fight the virus. Additionally, Evusheld will provide another prevention option for high-risk populations, alongside vaccines, including for people who are immunocompromised and unable to develop the needed degree of protective response following COVID-19 vaccination," AstraZeneca Singapore Country President Vinod Narayanan said.

A Phase III trial showed an 88% reduced risk of severe COVID-19 or death when patients with mild-to-moderate COVID-19 were treated within three days of symptom onset. AstraZeneca has this week received Emergency Use Authorization for Evusheld from the US Food and Drug Administration for the prevention of COVID-19 and has filed for regulatory approvals in other countries.

Follow the link for more news on

Join Healthcare Asia Magazine community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!